Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome

Exclusion Criteria

• •Patients on oral contraceptives. A two-month washout period will be required prior to screening for patients on these agents. A one-month washout will be required for patients on oral cyclic progestins. Patients on depo-progestins or hormonal implants are excluded.
• •Patients with liver disease defined as ALT or AST above normal range of each participating center, or total bilirubin\>30umol/L. Metabolic dysfunction-associated steatotic liver disease (MASLD) with normal ALT and AST can be included.
• •Patients with anemia (Hemoglobin \< 12 g/dL) or neutropenia (neutrocyte \<1.8×10\^9/L).
• •Patients with renal disease defined as serum creatinine\> 115umol/L.
• •Patients diagnosed with other endocrine diseases that are known to cause secondary polycystic ovary morphology, e.g., Cushing's syndrome, hyperprolactinemia, congenital adrenal hyperplasia (21-hydroxylase deficiency or other enzyme deficiency), hypothyroidism, etc.
• •Patients diagnosed with Type 1 or Type 2 diabetes.
• •Patients with known heart disease, like heart failure, atrial fibrillation, coronary heart disease, etc.
• •Patients with a history of any type of cancer.
• •Patients taking other medications known to affect reproductive function or metabolism. These medications include GnRH agonists and antagonists, antiandrogens, gonadotropins, GLP-1 receptor agonist, SGLT2i, metformin and thiazolidinediones. The washout period on all these medications will be two months.
• •Patients who have undergone a bariatric surgery procedure within the past 12 months.